Rockefeller Capital Management L.P. Has $11.36 Million Stake in GSK plc (NYSE:GSK)

Rockefeller Capital Management L.P. trimmed its stake in shares of GSK plc (NYSE:GSK - Free Report) by 6.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 335,831 shares of the pharmaceutical company's stock after selling 23,398 shares during the quarter. Rockefeller Capital Management L.P.'s holdings in GSK were worth $11,359,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Indiana Trust & Investment Management Co grew its position in shares of GSK by 200.0% during the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock valued at $25,000 after buying an additional 500 shares during the last quarter. Crews Bank & Trust bought a new position in shares of GSK during the fourth quarter valued at approximately $26,000. ST Germain D J Co. Inc. raised its position in shares of GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock worth $27,000 after purchasing an additional 522 shares during the period. Sierra Ocean LLC bought a new stake in shares of GSK in the 4th quarter worth approximately $32,000. Finally, Parkside Financial Bank & Trust boosted its position in GSK by 470.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock valued at $34,000 after purchasing an additional 818 shares during the period. Institutional investors own 15.74% of the company's stock.

GSK Stock Up 0.5 %

NYSE GSK traded up $0.20 on Monday, reaching $36.13. The stock had a trading volume of 543,758 shares, compared to its average volume of 4,646,778. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.93. The business has a 50 day moving average price of $37.43 and a 200 day moving average price of $36.07. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. The company has a market capitalization of $74.53 billion, a price-to-earnings ratio of 22.74, a P/E/G ratio of 1.12 and a beta of 0.56.

GSK (NYSE:GSK - Get Free Report) last posted its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. On average, analysts forecast that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, April 10th. Shareholders of record on Friday, February 21st were given a dividend of $0.3932 per share. This is a positive change from GSK's previous quarterly dividend of $0.39. The ex-dividend date was Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a yield of 4.35%. GSK's payout ratio is currently 100.63%.

Analyst Ratings Changes

A number of research firms have issued reports on GSK. StockNews.com cut GSK from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, April 16th. Morgan Stanley assumed coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating for the company. Finally, BNP Paribas began coverage on GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price objective on the stock. Eight investment analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $40.58.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.